New hope for Hard-to-Treat myeloma: targeted drug combo faces off against standard care
NCT ID NCT06868654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people with multiple myeloma that has come back or stopped responding to treatment. About 72 participants in China will be randomly assigned to one of the two groups. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (a targeted antibody-drug conjugate)
What this could lead to
If it works, this could offer a new treatment option for people with multiple myeloma that has returned or not responded to prior therapy.
What could go wrong
This is an early-stage Phase 3 trial with only 72 participants in China. The drug may not prove better than the current standard, and side effects like eye problems are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Beijing, China
-
GSK Investigational Site
Changchun, China
-
GSK Investigational Site
Guangzhou, China
-
GSK Investigational Site
Hangzhou, China
-
GSK Investigational Site
Jinan, China
-
GSK Investigational Site
Nanjing, China
-
GSK Investigational Site
Shenyang, China
-
GSK Investigational Site
Suzhou, China
-
GSK Investigational Site
Tianjin, China
-
GSK Investigational Site
Wuhan, China
-
GSK Investigational Site
Zhengzhou, China